An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

Clinical trial NCT04113616 · TERMINATED

Trial details

NCT number: NCT04113616
Sponsor: Kartos Therapeutics, Inc.
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Relapsed or Refractory Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)

Start date: 2019-09-25
Primary completion: 2023-09-27
Enrollment: 70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.